Short answer
Ispire Technology Inc. (ISPR) filed its fiscal 2025 10-K annual report with the SEC on Sep 15, 2025. It reported revenue of $127M (−16.1% year over year) and net income of −$39M.
- Top risk flagged: Regulatory risk: FDA approval requirement and high costs for marketing nicotine vaping products in the United States
FY2025 key financial metrics · XBRL
- Revenue
- $127M
- −16.1% YoY
- Net income
- −$39M
- −165.7% YoY
- Operating margin
- -29.7%
- −20.5 pp YoY
- Gross margin
- 17.8%
- −1.8 pp YoY
- EPS (diluted)
- −$0.69
- −155.6% YoY
- ROE
- -6489.3%
- −6446.4 pp YoY
- Operating cash flow
- −$7M
- +59.7% YoY
Source: XBRL data from the Ispire Technology Inc. (ISPR) FY2025 10-K on SEC EDGAR. USD.
Ispire Technology Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: R&D, design, sales, and distribution of vaping hardware for nicotine and cannabis global markets
- New product: Introduced proprietary Ispire ONE™ tech in June 2023 to enhance manufacturing consistency, safety, and reduce leaks/spitting
- Strategic shift: Started manufacturing assembly in Malaysian facility in Feb 2024 with focus on in-house production and ISO-certified quality
- Quantitative highlight: FY25 revenue $127.5M, down from $151.9M in FY24, with OEM/ODM sales growing to 40.2% of e-cigarette revenue vs 25.9% prior
- Noteworthy fact: Patented dual-coil tech enables optimized heating for separate cannabis oil and terpene vaporization, enhancing flavor and efficiency
Management Discussion & Analysis
- Fundraising rounds raised net proceeds of $18.3M (IPO), $7.4M (June 2023 private placement), $10.6M (March 2024 public offering)
- Capital deployed on Malaysia manufacturing facility, joint venture with Berify and Chemular, working capital, and R&D
- Regulatory risk noted as key emerging risk with potential market disruptions from changing nicotine and cannabis product laws
- Forward-looking emphasis on expanding international sales network and compliance amid evolving e-cigarette regulation
Risk Factors
- Regulatory risk: FDA approval requirement and high costs for marketing nicotine vaping products in the United States
- Macroeconomic threat: 16.1% revenue decline driven by $30.5 million U.S. product sales drop amid cannabis industry federal uncertainty
- Supply chain vulnerability: Dependence on Shenzhen Yi Jia for vaping products accounts for majority of cost of revenue
- Competitive risk: Changing adult consumer preferences impact ability to develop and market nicotine and cannabis vaping products
- Financial risk: Increased allowance for credit losses to $18.0 million in 2025 from $5.9 million in 2024, reflecting collection difficulties
Generated from the filing text; verify against the original. How to read a 10-K
Other Ispire Technology Inc. annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.